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HLA-G, a nonclassical HLA molecule uniquely expressed in the
placenta, is a central component of fetus-induced immune toler-
ance during pregnancy. The tissue-specific expression of HLA-G,
however, remains poorly understood. Here, systematic interrogation
of the HLA-G locus using massively parallel reporter assay (MPRA)
uncovered a previously unidentified cis-regulatory element 12 kb
upstream of HLA-G with enhancer activity, Enhancer L. Strikingly,
clustered regularly-interspaced short palindromic repeats (CRISPR)/
Cas9-mediated deletion of this enhancer resulted in ablation of
HLA-G expression in JEG3 cells and in primary human trophoblasts
isolated from placenta. RNA-seq analysis demonstrated that Enhancer
L specifically controls HLA-G expression. Moreover, DNase-seq and
chromatin conformation capture (3C) defined Enhancer L as a cell
type-specific enhancer that loops into the HLA-G promoter. Interest-
ingly, MPRA-based saturation mutagenesis of Enhancer L identified
motifs for transcription factors of the CEBP and GATA families essen-
tial for placentation. These factors associate with Enhancer L and
regulate HLA-G expression. Our findings identify long-range chroma-
tin looping mediated by core trophoblast transcription factors as the
mechanism controlling tissue-specific HLA-G expression at the mater-
nal–fetal interface. More broadly, these results establish the combi-
nation of MPRA and CRISPR/Cas9 deletion as a powerful strategy to
investigate human immune gene regulation.
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During pregnancy, a semiallogeneic fetus expressing pater-nally derived antigens is nurtured for months without suf-
fering rejection by the maternal immune system (1). This state of
immune tolerance is established at a precise anatomical location,
the placenta, a transient organ consisting of fetal trophoblasts and
a specialized uterine mucosa, the decidua. During implantation,
HLA-G+ extravillous trophoblasts (EVTs) invade the maternal
tissue, defining the boundary between mother and fetus (2).
HLA-G, a nonclassical nonpolymorphic major histocompatibility
complex (MHC) class I molecule, is uniquely expressed by EVTs (3,
4), where it plays a central role in inducing immune tolerance.
Several inhibitory receptors present on natural killer (NK) cells, the
most abundant immune cell type at the maternal–fetal interface,
and on myeloid cells, have been shown to bind to HLA-G (5–7). An
HLA-G cycle between decidual NK cells and EVTs provides for
both NK cell tolerance and antiviral immunity (8–10). Importantly,
HLA-G is sufficient to inhibit NK cell cytotoxicity (11) and required
to protect trophoblasts against NK cell-induced lysis (12). Several
pregnancy-related disorders, including miscarriage, recurrent fetal
loss, and preeclampsia, have been associated with polymorphisms
resulting in reduced HLA-G expression levels (13, 14). In-
triguingly, HLA-G expression has also been detected in tumor
lesions, where it may facilitate immune evasion (15, 16). However,
despite substantial effort, the mechanism by which the EVT-
specific expression of HLA-G is obtained has remained elusive
for more than two decades (13, 17, 18).
Tissue-specific gene expression is primarily regulated at
the level of transcription by distant cis-regulatory elements—
enhancers (19, 20). Traditionally, enhancer discovery has relied
on examining features predictive of enhancer activity, such as
chromatin accessibility, DNA and chromatin covalent modifi-
cations, and sequence conservation between species (21). This
approach has been successfully used to gain important insights
into immune gene regulation, such as the discovery of enhancers
controlling the expression of murine Foxp3, a transcription factor
governing the commitment and stability of regulatory T cells (22).
However, substantial differences in regulatory sequences between
species limit the ability to derive conclusions from model organ-
isms regarding human gene regulation. In particular, the MHC
locus differs significantly between mouse and humans (23), and
HLA-G lacks a clear ortholog in mice.
In this study, we used an unbiased high-throughput approach,
massively parallel reporter assay (MPRA) (24), to interrogate a
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27-kb region spanning the HLA-G locus for functional activation
of transcription. Our results uncover a private enhancer, which
controls the tissue-specific expression of HLA-G at the maternal–
fetal interface, and provide a relevant methodology to dissect hu-
man immune gene regulation without prior sequence knowledge.
Results
Identification of a Trophoblast-Specific Enhancer 12 kb Upstream of
HLA-G. To systematically interrogate the HLA-G locus for active
cis-regulatory elements, we set up a MPRA screen (24). For this
purpose, 12,000 partially overlapping 121-bp-long elements (tiles)
spanning 27 kb of the HLA-G locus were synthesized, coupled to
unique DNA tags, and cloned into plasmids containing an invariant
promoter and a firefly luciferase reporter gene. For greater con-
fidence, two different promoters were used in parallel libraries, a
strong promoter (SV40P) and a minimal TATA box synthetic
promoter (minP). The resulting libraries were cotransfected into
JEG3 cells, an HLA-G+ choriocarcinoma cell line commonly used
to model EVTs (25). To measure the relative enhancer activity of
each tested element, we performed high-throughput sequencing
and quantified the relative abundance of each element’s tag reads
in mRNA isolated from the transfected cells and in the pooled
libraries. Enhancer activity was calculated as the median (cDNA
count divided by the DNA count) of tags representing a tile, di-
vided by the median ratio for all tags in a library. Nominal
candidates were defined as any tile where enhancer activity
measurements were >1 and P values were <0.05 for both bi-
ological replicates of each library transfection.
Our unbiased MPRA screen yielded several enhancer candidates
upstream of HLA-G (Fig. 1A). The four most confident hits, in-
dicated in Fig. 1 A and B, were then carried on for further analysis
using classical luciferase reporter gene assays. The most confident
candidate, located 12 kb upstream of theHLA-G gene, was the only
tile with enhancer activity greater than 2 with both promoters
tested, displaying the highest enhancer activity with minP (8.4) and
second highest enhancer activity with SV40P (12.4) overall. This
region specifically enhanced firefly luciferase activity upstream of
the minimal promoter by 20-fold in HLA-G+ JEG3 cells (Fig. 1C).
We named this previously unidentified putative regulatory element
Enhancer L, for being a long-range enhancer discovered with our
unbiased enhancer screen. Importantly, Enhancer L was not active
in HEK293T cells, an HLA-G–negative control cell line (Fig. 1D).
Moreover, this cell type-specific activity pattern was maintained
even when Enhancer L was cloned in an inverted orientation (Fig.
1D), a classical hallmark of an enhancer element (19). Of note,
candidate numbers 3 and 4 from our MPRA screen, located near or
even partially overlapping with Enhancer L, respectively, displayed
negligible activity in JEG3 cells (Fig. 1C). Altogether, these ob-
servations suggest that Enhancer L corresponds to a narrowly
defined regulatory region in the HLA-G locus that may confer
tissue-specific HLA-G expression to trophoblasts.
Enhancer L Is Essential for HLA-G Expression in JEG3 Cells. Next, we
sought to investigate whether Enhancer L modulates endogenous
HLA-G expression. To directly target Enhancer L in JEG3 cells, we
used a clustered regularly-interspaced short palindromic repeats
(CRISPR)/Cas9 dual-guide approach (26, 27) by targeting two guide
RNAs (gRNAs) to sites flanking Enhancer L (Fig. 2A). We used a
Streptococcus pyogenes Cas9 linked via a self-cleaving 2A peptide to
a green fluorescent protein (GFP) to facilitate identification of
Cas9-expressing cells. GFP+ cells were sorted and plated at clonal
density and the emerging single-cell–derived colonies were trans-
ferred 10 d postplating into 96-well plates. PCR analysis of CRISPR/
Cas9 targeted single-cell–derived clones was used to identify ho-
mozygous Enhancer L KO clones (Fig. 2B). We observed a clonal
targeting efficiency of 29.5%, with homozygous deletions occurring
at a frequency of 8.7%. Four independent Enhancer L-null clones
and three WT clones were selected for further characterization. As
expected, Sanger sequencing demonstrated excision of the DNA
between the predicted Cas9 cleavage sites (three bases 5′ of the
PAM sequence), with three out of four clones having the same exact
deletion of 154 bp (Fig. 2C).
Strikingly, deletion of Enhancer L resulted in complete abla-
tion of HLA-G expression, as determined by flow cytometry (Fig.
2D) and quantitative real-time PCR (qRT-PCR) (Fig. 2E). Sur-
veying the whole genome for chromatin accessibility using ge-
nome-wide DNase-seq revealed that Enhancer L is located within
a DNase I hypersensitivity site (DHS) in JEG3 cells (Fig. 2C),
supporting the hypothesis that Enhancer L is indeed an active
regulatory element in its endogenous chromatin context.
Deletion of Enhancer L in JEG3 Cells Uniquely Ablates HLA-G Expression.
Following our observation that Enhancer L is required for HLA-G
expression, we then asked whether Enhancer L acts specifically on
HLA-G. Previous studies have identified enhancers that affect
multiple genes spanning regions of hundreds of kilobases (28, 29).
To investigate whether Enhancer L also regulates other genes in the
HLA locus or elsewhere on chromosome 6, we sequenced polyA+
mRNA from three Enhancer L KO JEG3 clones, as well as three
WT clones and two independent samples of the parental JEG3 cell
line as controls. RNA-seq confirmed that HLA-G is completely
ablated across all KO clones (Fig. S1A), and that it is the only such
gene within 2 Mb of Enhancer L (Fig. S1B), suggesting that HLA-G
is the only direct cis target of Enhancer L. Looking beyond




Fig. 1. Enhancer L is a trophoblast-specific enhancer upstream of HLA-G. (A)
Massively parallel reporter assay (MPRA) covering the HLA-G locus. Enhancer
activity of tiles upstream of the minP (circles) and SV40P (squares) promoters,
calculated as the median count of any tags representing a tile, divided by the
median ratio for all tags in the library, plotted against genomic coordinates
(genome build hg19). Only tiles with P < 0.05 for both biological replicates
are shown. Top-ranked tiles are numbered in decreasing order of confi-
dence. The most confident hit (1) is in red type, and the region surrounding
it is highlighted with a red box. (B) Schematic representing the location of
the most confident hits from the MPRA relative to HLA-G, together with a
negative control region (Neg). (C) Enhancer L, marked in red, was found to
be active in JEG3 cells (HLA-G+), as determined by luciferase reporter gene
activity in combination with the minP promoter. Control, empty vector; Neg,
negative control region. (D) Enhancer L remains active specifically in JEG3
cells when its direction is inverted. Control, empty vector; “L recnahnE,”
inverted Enhancer L; RLU, relative luciferase units. Error bars represent SEM
of three independent experiments.
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significant differences in the expression of 321 genes using Cuffdiff
[false-discovery rate (FDR) < 0.05]. To rule out the possibility that
these changes were caused by CRISPR/Cas9-induced off-target
effects, we performed in silico off-target analyses of our Enhancer L
gRNAs using the CRISPR design tool at crispr.mit.edu (30). The
top 50 predicted off-target sites yielded maximum scores of 3.3 for
gRNA 1, and 0.9 for gRNA 2 (out of 100), suggesting that the
observed global changes in gene expression are not likely to be a
result of off-target cleavage at these sites. Gene set enrichment
analysis (GSEA) of the most differentially expressed genes revealed
statistically significant enrichment (FDR < 0.05) for six gene sets, all
of which are related to steroid hormone biosynthesis and G-protein–
coupled receptor signaling, processes expected to play a role in
trophoblast physiology. Pairwise comparison of all three experi-
mental groups (WT, KO, parental JEG3), however, revealed that,
despite the observed transcriptome-wide changes in gene expres-
sion, HLA-G was by far the most down-regulated gene upon En-
hancer L deletion at the whole-transcriptome level (Fig. S1C),
indicating that Enhancer L uniquely modulates HLA-G expression.
Enhancer L Is Required for HLA-G Expression in Primary EVTs. To
confirm the role of Enhancer L in primary human trophoblasts,
we obtained villi from first-trimester human placental tissue and
purified HLA-G+ EVTs by flow cytometry (31). Cas9-2A-GFP
and gRNAs targeting Enhancer L were successfully codelivered
into primary EVTs using lentiviral particles, as assessed by GFP
expression (Fig. 3A). As expected, Enhancer L deletion resulted
in a significant decrease in HLA-G mRNA levels [74.12 ± 13.61%
(SEM); n = 3] (Fig. 3B).
Loss of HLA-G surface expression as a result of lentiviral
CRISPR/Cas9-mediated ablation of Enhancer L was first eval-
uated in JEG3 cells, which divide rapidly in culture. We observed
complete loss of HLA-G surface expression 1 wk posttransduction
in a large percentage of transduced cells [61.9 ± 1.93% (SEM);
n = 3] (Fig. S2A). Detecting changes in HLA-G surface expression
in primary EVTs, however, is hampered by the unusually long
half-life of HLA-G protein on the cell membrane (32), and the
fact that primary EVTs can only be cultured ex vivo for a short
period (<5 d). Despite these technical limitations, we were able
to detect a significant reduction in HLA-G surface expression 5 d
after targeting Enhancer L in primary EVTs [60.71 ± 10.68%
(SEM); n = 3] (Fig. 3 C and D, and Fig. S2B). Successful genomic
deletion of Enhancer L was confirmed by PCR sequencing (Fig. S2
C and D). Our results demonstrate that Enhancer L is indeed
necessary for HLA-G expression in primary human EVTs.
Enhancer L Is a Distant Regulatory Element That Loops into the HLA-G
Proximal Promoter.Next, we aimed to characterize the mechanism
by which Enhancer L activates HLA-G expression at a distance.
The current model of long-range gene regulation postulates that
remote cis-regulatory elements come into close proximity to the
promoters of the genes they regulate via chromatin looping (33). To
test for the involvement of looping in Enhancer L–HLA-G pro-
moter long-range communication, we carried out chromatin con-
formation capture (3C) assays in JEG3 and HLA-G–negative
HEK293T cells (Fig. S3 A and C, and Materials and Methods).
We detected a looping interaction between Enhancer L and the
classical promoter of HLA-G specifically in JEG3 cells (Fig. S3B),
confirming the nature of the resulting hybrid DNA molecule con-
sisting of Enhancer L and the proximal promoter by sequencing




Fig. 2. Enhancer L is required for HLA-G expression in the JEG3 trophoblast
cell line. (A) Dual-CRISPR guide strategy to delete Enhancer L. Arrows rep-
resent the primers used for PCR screening. (B) PCR screening of CRISPR/Cas9-
targeted JEG3 single-cell–derived clones. Green*, wild type; yellow*, het-
erozygote; red*, null clone. (C) Sanger sequencing of four independent
homozygous Enhancer L KO clones and three independent WT clones
resulting from CRISPR/Cas9 targeting of Enhancer L (black box) in JEG3 cells
using a dual-CRISPR guide RNA approach. Binding sites for the gRNAs tar-
geting Enhancer L are underlined and shaded. PAM motifs are italicized in
green type. Enhancer L is part of a DNase I hypersensitive site (DHS) in JEG3
cells, as determined by genome-wide DNase-seq. EL, Enhancer L. (D) Com-
bined FACS histogram demonstrating complete ablation of HLA-G surface
expression in Enhancer L KO JEG3 clones. (E) HLA-G transcript levels of En-
hancer L KO clones, with JEG3 cells and HEK293T cells as controls. Gene
expression normalized to GAPDH expression. Error bars represent SEM of




















































Fig. 3. Enhancer L is necessary for HLA-G expression in primary extravillous
trophoblasts (EVTs). (A) Transduction of first-trimester HLA-G+ EVTs with
lentiviral Cas9 and Enhancer L gRNAs, assessed based on GFP expression. BF,
bright-field (40× magnification). (B) Reduction of HLA-G expression at the
mRNA level following Enhancer L deletion. Bars represent average ± SEM of
three independent experiments. Gene expression normalized to GAPDH
expression. *P < 0.05, paired Student’s t test. EL, Enhancer L. (C) Enhancer
L deletion leads to significant reduction in HLA-G surface expression in pri-
mary EVTs, as assessed by FACS. One representative experiment is shown
(n = 3). (D) Significant reduction in HLA-G surface expression upon Enhancer
L deletion in primary EVTs [mean fluorescence intensity (MFI)]. Bars repre-
sent average ± SEM of three independent experiments. *P < 0.05, paired
Student’s t test.





















HEK293T cells (Fig. S3B), in agreement with the lack of En-
hancer L activity in these cells (Fig. 1D).
MPRA-Based Scanning Mutagenesis Reveals Motifs Controlling Enhancer L
Activity. Having established Enhancer L as a bona fide enhancer
upstream of HLA-G, we sought to identify the transcriptional regu-
lators that mediate its action. To our surprise, truncation of Enhancer
L invariably led to loss of enhancer activity in firefly luciferase re-
porter gene assays, suggesting multiple active motifs spread across its
length (Fig. S4A). To fine map the active regulatory motifs re-
sponsible for Enhancer L activity, we carried out an MPRA-based
scanning mutagenesis at the single-base pair resolution (24). In brief,
we generated a total of 12,000 Enhancer L variants, representing all
possible single substitutions, as well as small insertions or deletions at
all positions. To reduce experimental noise, each variant was coupled
to 16 tags on average, for a total of 200,000 distinct variant–tag
combinations. As before, this complex library was cotransfected into
JEG3 cells, followed by RNA harvesting and sequencing analysis.
This fine mapping of Enhancer L led to the identification of five
putative regulatory motifs, consistent across both promoters tested
(SV40P and minP) (Fig. 4A and Fig. S4B). Reporter gene assays with
truncated versions of Enhancer L lacking each one of these motifs
(M1 through M5) showed that each one of them is essential for
optimal Enhancer L activity in JEG3 cells (Fig. S4C). Subsequent in
silico analysis using the TRANSFAC database (34) predicted binding
of CEBP and GATA family transcription factors within these five
motifs (Fig. 4A and Fig. S4B).
CEBP and GATA Factors Regulate Trophoblast-Specific HLA-G Expression.
Motif sequence analysis alone does not allow discrimination between
different members of transcription factor families. We reasoned that
the transcription factors controlling HLA-G expression via Enhancer
L must be highly expressed specifically in HLA-G+ trophoblasts.
Microarray analysis of primary cells isolated from human placental
tissue, and JEG3 cells (31), revealed that CEBPA, CEBPB, GATA2,
and GATA3 are the most highly expressed genes within their re-
spective transcription factor families (Fig. 4B). Our whole-tran-
scriptome RNA-seq analysis (Fig. 4C) confirmed high expression
levels of CEBPB, GATA2, and GATA3 in JEG3 cells. In addition, a
survey of publicly available gene expression profiles (BioGPS)
revealed that these three transcription factors are highly coexpressed
in human placenta, and also more restricted in expression to this
tissue than any other CEBP or GATA transcription factor family
member. Importantly, CEBPβ, GATA2, and GATA3 have been
implicated in murine placental development and trophoblast-specific
gene regulation (35–37), making them strong candidates for tran-
scriptional regulators of HLA-G expression in human trophoblasts.
To test our prediction, we sought to determine whether CEBPβ,
GATA2, and GATA3 bind to Enhancer L. Indeed, chromatin
immunoprecipitation (ChIP) using validated ChIP-grade anti-
bodies, followed by qPCR analysis (ChIP-qPCR), revealed a 40-
fold enrichment for CEBPβ on Enhancer L (Fig. 4D). Similarly, a
significant enrichment for GATA2 and GATA3 (fivefold) was
detected on Enhancer L (Fig. 4E), indicating that, in JEG3 cells,
endogenous CEBPβ, GATA2, and GATA3 associate with En-
hancer L. In addition, all three factors were found to bind to the
proximal promoter of HLA-G (Fig. 4 D and E), providing further
evidence for the existence of a chromatin loop between Enhancer
L and the core promoter of HLA-G, possibly established by
GATA2 and GATA3 (38, 39). Of note, Pol II associated with both
Enhancer L and the HLA-G core promoter (Fig. S4D), suggesting
that active transcription is involved in the formation of this long-
range chromatin loop. Consistent with a role in HLA-G tran-
scriptional activation, transient overexpression of CEBPβ, GATA2,
and GATA3 individually in JEG3 cells led to an up to eightfold
increase in HLA-G expression, indicating that these three factors
are transcriptional activators of HLA-G expression (Fig. 4F). Taken
together, our data support a model where CEBPβ and GATA2/3
mediate long-range chromatin interactions between Enhancer
L and the classical promoter of HLA-G (Fig. 4G), driving HLA-G
expression specifically in EVTs at the maternal–fetal interface.
Discussion
Genome-wide association studies (GWAS) have uncovered an
astonishing number of disease-associated noncoding loci (40),
posing a challenge to functionally validate and characterize putative
regulatory elements. MPRA represents an unbiased high-through-





Fig. 4. Trophoblast CEBP and GATA factors regulate HLA-G expression.
(A) Identification of five putative regulatory motifs required for Enhancer L
activity using MPRA-based scanning mutagenesis in combination with an
SV40 promoter. Red bars indicate a significant change from original En-
hancer L activity (Mann–Whitney U test, 5% FDR); blue bars, not significant.
The matrix represents the estimated additive contribution of each nucleotide
to Enhancer L activity. Transcription factor binding site prediction was per-
formed using the TRANSFAC database. (B) Expression levels of genes belong-
ing to the two transcription factor families predicted to bind to Enhancer L,
CEBP and GATA, according to published microarray data. The heat map was
generated using GenePattern, with dark blue representing lowest expression,
and dark red, highest expression. DSC, decidual stromal cells. (C) CEBP and
GATA gene expression levels in JEG3 cells, as determined by whole-tran-
scriptome RNA-seq. FPKM, fragments per kilobase of exon per million frag-
ments mapped. (D and E) CEBPβ, the most highly expressed CEBP transcription
factor in JEG3 cells (D), and GATA2 and GATA3, the most abundant GATA
factors in JEG3 cells (E), associate with Enhancer L and with the HLA-G classical
promoter, as assessed by ChIP-qPCR (n = 2). Control, positive control region
predicted to be bound by the respective transcription factor according to
ENCODE data; HBB promoter, negative control. (F) Ectopic expression of
CEBPβ, GATA2, or GATA3 up-regulate HLA-G expression in JEG3 cells, as
measured by qPCR. The transcription factor ETS2 was used as a negative
control. Control, empty vector. Error bars represent SEM of replicates of a
representative experiment (n = 2). (G) Proposed model of trophoblast-specific
HLA-G transcriptional regulation by CEBPβ, GATA2, and GATA3 via Enhancer L.
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regions. In this study, the most confident candidate from our
MPRA screen, located 12 kb upstream of HLA-G, was found to
be active specifically in the HLA-G+ JEG3 choriocarcinoma
cell line (Fig. 1), suggesting that it may be involved in tissue-
specific HLA-G transcriptional regulation. Indeed, CRISPR/
Cas9 genome editing revealed that this previously unidentified
enhancer, Enhancer L, is essential for trophoblast expression of
HLA-G (Figs. 2 and 3, and Figs. S1 and S2).
Previous studies established that MHC gene expression is
mainly controlled at the level of a conserved proximal promoter.
Upon interaction with a transcriptional activator—CIITA for
class II and NLRC5 for class I genes—a multiprotein transcription
factor complex is assembled, forming the MHC enhanceosome
(17, 41, 42). Even though the enhanceosome is essential for basal
and induced expression of MHC class I genes, its relevance in
trophoblasts is uncertain: EVTs do not express NLRC5 or CIITA
(31) and the HLA-G proximal promoter harbors several non-
functional motifs (18), suggesting that tissue-specific HLA-G ex-
pression is mediated by a distinct mechanism. Although several
studies have described cis-regulatory regions involved in HLA-G
transcriptional regulation (13, 43, 44), the present study is the first
(to our knowledge) to report a noncoding sequence, Enhancer L,
absolutely required for the tissue-specific expression of HLA-G
in trophoblasts.
Interestingly, Enhancer L is contained within a long terminal
repeat (LTR) sequence, LTR7 (45), associated with a human
endogenous retroviral element (ERV), ERV1, as indicated in
Fig. S5A. LTR sequences have been co-opted by mammalian
genomes as regulatory elements, especially in the placenta (46).
Well-known examples include the placenta-specific promoter of
CYP19 (47) and MER20, regulatory sequences found upstream
of progesterone-responsive genes essential for decidualization
(48). Enhancer L sequence is unique in the human genome and
well conserved across apes and Old World monkeys, yet absent
in New World monkeys (Fig. S5 A and B), where HLA-G ap-
pears to be a classical MHC molecule (49–51). Intriguingly, the
orangutan genome, the only ape genome containing a functional
HLA-G promoter (X2 and Y cis-elements matching those in
the HLA-A promoter; Fig. S5C), does not harbor the Enhancer
L sequence. In addition, similar to New World monkeys, the
orangutan HLA-G ortholog is a polymorphic MHC molecule.
Perhaps in orangutans, because they are predominantly monog-
amous and thus less exposed to allogeneic fetuses (49), HLA-G
functions as a classical antigen-presenting molecule. The obser-
vation that Enhancer L is only found in genomes that lack a
functional HLA-G classical promoter raises the possibility that a
retroviral element was co-opted during evolution to function in
trophoblast-specific tolerogenic MHC expression.
Previous literature suggests that differential expression of
transcription factors plays a role in cell type-specific HLA-G
transcription. The identity of such factors, however, has remained
elusive (52, 53). In our study, MPRA-based saturation mutagen-
esis allowed us to fine map the regulatory elements responsible for
Enhancer L activity, ultimately pointing toward CEBP and GATA
factors as candidates for transcriptional activators of HLA-G ex-
pression in trophoblasts (Fig. 4). Indeed, ChIP and transient
transfection studies revealed that CEBPβ, GATA2, and GATA3
associate with Enhancer L (Fig. 4 D and E) and are positive reg-
ulators of HLA-G expression (Fig. 4F).
3C revealed that Enhancer L loops across a 12-kb distance into
the classical promoter ofHLA-G (Fig. S3). Consistent with this long-
range chromatin interaction, genome-wide DNase-seq demonstrated
that Enhancer L is part of a DHS specifically in HLA-G+ JEG3 cells
(Fig. 2C and Fig. S6). Publicly available ChIP-seq data indicates
CTCF binding flanking Enhancer L and the HLA-G coding se-
quence (Fig. S6). This CTCF binding pattern suggests the exis-
tence of an insulated chromatin domain (54) for HLA-G
transcriptional regulation, corroborated by our observation that
Enhancer L deletion does not significantly alter the expression
of any gene other than HLA-G on chromosome 6 (Fig. S1).
Interestingly, a long-range chromatin interaction mediated by
the insulator CTCF has been described in the MHC class II
locus (55). Our data suggest that the looping interaction be-
tween Enhancer L and the promoter of HLA-G is mediated by
GATA2/3, possibly in association with CEBPβ (38, 39, 56).
In conclusion, we have demonstrated that trophoblast HLA-G
expression is contingent upon the activity of a remote enhancer,
Enhancer L. Our data are consistent with a model where CEBPβ
and GATA2/3 associate with Enhancer L, are recruited to the
core promoter of HLA-G via chromatin looping, and up-regu-
late HLA-G expression (Fig. 4G). These findings establish
chromatin looping mediated by lineage-specific transcription
factors as a mechanism governing tissue-specific immune gene
expression at the maternal–fetal interface. Future studies fur-
ther dissecting the transcriptional regulation of HLA-G will not
only shed light on immune privilege during pregnancy, but may
also enable us to specifically control HLA-G expression to in-
duce tolerance in transplantation therapies.
Materials and Methods
All of the human tissue used for this research was deidentified, discarded
clinical material. The Committee on the Use of Human Subjects [the Harvard
institutional review board (IRB)] determined that this use of all of this hu-
man material is exempt from the requirements of IRB review.
Cell Culture. JEG3 and HEK293T cells were cultured in RPMI-1640 medium
(Gibco) supplemented with 10% (vol/vol) FBS, Glutamax, and penicillin–strep-
tomycin. Transfections were carried out using FuGENE 6 (Promega) according
to the manufacturer’s instructions and analyzed 48 h posttransfection.
Flow Cytometry. Cells were harvested, blocked in 4% (vol/vol) FBS for 30 min,
stained with HLA-G PE (cloneMEMG/9; Abcam) in 1% FBS for 1 h, washed thrice,
and resuspended in 1% FBS. Cells were acquired using either a FACSCalibur or an
LSR-II instrument (BD Biosciences) and analyzed with FlowJo (Tree Star) software.
qRT-PCR Analysis. Total RNA was isolated using TRIzol (Life Technologies),
according to manufacturer’s instructions. A total of 1,500 ng of RNA was
used for cDNA synthesis with the qScript cDNA SuperMix (Quanta Biosci-
ences). A total of 30 ng of cDNA was used per qRT-PCR, performed using
SYBR Green (Life Technologies) on a ViiA7 system real-time PCR system (Life
Technologies). Target gene expression levels were normalized to GAPDH.
Primer pairs used are listed in Table S1.
Details of molecular biology, MPRA, luciferase reporter gene assay, ge-
nome-wide DNase-seq, 3C, CRISPR/Cas9 genome editing, transcriptome-wide
RNA-seq, first-trimester primary EVT isolation and transduction, and ChIP
(ChIP-qPCR) experiments are given in SI Materials and Methods.
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